Topas Therapeutics Extends its Series A to EUR 18 Million (USD 21 Million) with Boehringer Ingelheim Venture Fund
November 2, 2017
Corporate venture fund invests EUR 4 million (USD 5 million) into Topas Financing to accelerate clinical trials in autoimmune diseases Detlev Mennerich, Ph.D., Investment Manager